Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Immune gene signatures in human colorectal tumors with different GSNOR/ADH5 expression

ABSTRACT: Immune gene signatures in human colorectal tumors with different GSNOR/ADH5 expression

PROVIDER: PRJNA945046 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Immune gene signatures in human colorectal tumors with different GSNOR/ADH5 expression

Project description:The study was designed to explore the relationships between GSNOR/ADH5 expression and the tumor immune microenvironment

2023-03-17 | GSE227372 | GEO

Targeting metabolism to improve immunotherapy in GSNOR-deficient colorectal cancer

Project description:Colorectal cancer (CRC) is the third most diagnosed type of cancer and the second leading cause of cancer death worldwide. Despite the increasing knowledge of CRC molecular biology and the development of new targeted therapies, its high heterogeneity hampers the efficacy of current treatments. Thus, there is a pressing need to identify new effective therapeutic targets and improve immune therapies for these patients. In this regard, S-nitrosoglutathione reductase (GSNOR) is a denitrosylase enzyme that has been suggested to play a tumour suppressor role, although the mechanisms responsible are still largely unclear. Therefore, the main objective of this project was to understand the role of GSNOR in CRC tumorigenesis and its therapeutic implications. Firstly, we classified CRC tumours as GSNOR-high or low according to their GSNOR expression as assessed by immunohistochemistry (IHC). Accordingly, we found that GSNOR deficiency was associated with worse prognosis factors such as a larger tumour size at diagnosis, higher TNM stage, higher grade of tumour budding (TB), the CMS4 subtype, lower expression of the intestinal differentiation markers CDX2 and AE1/AE3 cytokeratin and a worse progression free survival (PFS) and overall survival (OS). We next investigated the differences in gene expression between CRC GSNOR-high and low tumours, uncovering significant alterations in metabolism and immune system pathways. Hence, GSNOR-deficient tumours were characterized by immune suppressive features and a dysregulation of their metabolism, favouring other metabolic pathways than OXPHOS.

2024-04-13 | GSE263844 | GEO

Targeting metabolism to improve immunotherapy in GSNOR-deficient colorectal cancer

Project description:Targeting metabolism to improve immunotherapy in GSNOR-deficient colorectal cancer

| PRJEB74195 | ENA

Targeting metabolism to improve immunotherapy in GSNOR-deficient colorectal cancer

Project description:Targeting metabolism to improve immunotherapy in GSNOR-deficient colorectal cancer

| PRJNA1099593 | ENA

Targeting metabolism to improve immunotherapy in GSNOR-deficient colorectal cancer

Project description:Targeting metabolism to improve immunotherapy in GSNOR-deficient colorectal cancer

| PRJEB74194 | ENA

Somatic L1 Retrotransposition of Colorectal Tumors

Project description:Somatic L1 Retrotransposition of Colorectal Tumors

| PRJNA173389 | ENA

Array CGH analysis of human colorectal tumors

Project description:The concept of the CpG island methylator phenotype (CIMP) in colorectal cancers (CRCs) is widely accepted, though the timing of its occurrence and its interaction with other genetic defects early during carcinogenesis remains largely unknown. Our aim was to uncover the molecular evolution of CIMP CRCs through integrative analysis of endoscopic, histological and molecular signatures in precancerous and malignant colorectal lesions. A total of 84 endoscopically obtained human colorectal tumor was analyzed using Agilent CGH microarray. Copy number aberration was compared with clinicopathological features and DNA methylation status.

2012-08-31 | E-GEOD-35476 | biostudies-arrayexpress

Gene expression signatures of the PRMS tumors.

Project description:Gene expression signatures of the PRMS tumors.

| PRJNA841565 | ENA

Microsatellite stable (n=38) and instable-high (n=13) human colorectal tumors assayed with Affymetrix HuGeneFL arrays.

Project description:mRNA assays were performed on 51 samples of human colorectal tumors using Affymetrix HuGeneFL arrays containing 7129 probe-sets. We compared 38 microsatelite stable (MSS) tumors with 13 microsatellite instable-high (MSI) tumors to form a list of genes differing between the two types. In order to identify molecular signatures characterizing MSI tumors, we examined only MSI-high cancers and not MSI-low ones. Keywords: disease state analysis Human samples of 38 microsatellie stable and 13 microsatellite instable-high colorectal tumors, each from a separate patient, had mRNA assays performed using Affymetrix HuGeneFL arrays, with 7129 probe-sets. A supplementary Excel file (Colon_HuFL_logs.xls) is attached below that gives the log-transformed probe-set values. It also gives the p-values from T-tests comparing these values between MSS and MSI samples, as well as an estimated average fold-difference, for which the mathematical functions are explicitly given.

2009-04-10 | E-GEOD-11543 | biostudies-arrayexpress

Microsatellite stable (n=38) and instable-high (n=13) human colorectal tumors assayed with Affymetrix HuGeneFL arrays.

2009-04-10 | GSE11543 | GEO